A PYMNTS Company

EU: AbbVie-Allergan US$63B deal cleared

By  |  January 12, 2020

The European Commission approved AbbVie’s merger with Allergan on the condition the companies sell off Allergan’s late-stage IL-23 inhibitor brazikumab. That stipulation is far from a deal-breaker; Allergan already offered to offload the med, which the EU claimed conflicted with AbbVie’s IL-23 candidate risankizumab, along with cystic fibrosis med Zenpep. 

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    In forcing Allergan to give up brazikumab, the EU aims to avoid antitrust concerns in the irritable bowel disease market. 

    “Our decision makes sure that the merger between AbbVie and Allerganwill not disrupt the development of a promising innovative treatment for these diseases,” said Margrethe Vestager, executive VP of EU Merger Regulation.

    Although a final decision from the Federal Trade Commission (FTC) has yet to come, the EU approval gives the first go-ahead to a megamerger expected to create the fourth-largest drugmaker in the world. In September, the FTC sent a “second request” for information on the deal to both drugmakers, giving hope to a coalition of unions and consumer groups that had asked the agency to “carefully examine” the deal and block it outright if necessary. 

    Full Content: Europa Press

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.